AN2 Therapeutics, Inc. (ANTX) delivered a return of 319.47% over the past year. Since ANTX does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in AN2 Therapeutics, Inc. one year ago would be worth $41,947 today, representing a gain of $31,947.

AN2 Therapeutics, Inc. (ANTX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For ANTX, the total return equals the price-only return.

Yes, AN2 Therapeutics, Inc. (ANTX) outperformed the S&P 500 by 296.61 percentage points over the past year. ANTX delivered a total return of 319.47%, compared to the S&P 500's 22.86%. This 296.61pp alpha means investors in ANTX earned more than a passive S&P 500 index fund.

AN2 Therapeutics, Inc. (ANTX) experienced a maximum drawdown of -45.60% over the past year, declining from its peak on 2026-03-10 to its trough on 2026-04-10. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are AN2 Therapeutics, Inc. (ANTX)'s long-term returns with dividends reinvested. Over 10 years, the total return is -39.4% (-4.9% CAGR) — $10,000 would have grown to $6,061. Over 20 years: -22.9% total return (-1.3% CAGR) — $10,000 → $7,713. Over 30 years: -22.9% total return (-0.9% CAGR) — $10,000 → $7,713. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

AN2 Therapeutics, Inc.'s best calendar year was 2023 with a total return of 110.8%. Its worst year was 2024 with a total return of -93.1%. This range shows the volatility investors should expect — the difference between the best and worst year is 203.9 percentage points.